Marinus Pharmaceuticals Shares Plummet Due to Seizure Treatment Trial Setbacks

1. Marinus Pharmaceuticals experienced a significant drop in share value, with a decline of over 80% on Monday.
2. The decline occurred after the company's seizure treatment failed to meet high expectations.
3. The drug in question was intended for adult focal onset seizures, and the trial results did not meet the late-stage criteria.
4. Marinus Pharmaceuticals also failed to meet early stopping criteria for a status epilepticus trial.
5. The company's seizure drug did not meet early stopping criteria for a study, leading to the disappointing performance.
6. As a result of the trial failures, Marinus has decided to jettison its seizure drug program.

These events occurred on or before Tuesday, April 16, 2024, as indicated by the provided search results.